In reasons released February 7, 2017, the Federal Court dismissed AstraZeneca’s application for a prohibition order regarding Mylan’s naproxen-esomeprazole product until after the expiration of Patent No. 2,449,098AstraZeneca Canada Inc v Mylan Pharmaceuticals ULC2017 FC 142. The Court found that Mylan’s allegation of invalidity on the basis of obviousness was justified.